Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1F | P30939 | 18/20 | 0.51 |
| ▸ | HTR1D | P28221 | 13/20 | 0.51 |
| ▸ | HTR1B | P28222 | 12/20 | 0.51 |
| ▸ | HTR1A | P08908 | 10/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | HTR2A | P28223 | 1/20 | 0.42 |
| ▸ | HTR2C | P28335 | 1/20 | 0.42 |
| ▸ | HTR1E | P28566 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6722057 | 0.94 | HTR1F (0.47) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL6724677 | 0.88 | HTR1F (0.42) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL6670992 | 0.85 | HTR1F (0.47) | HTR1FHTR1DHTR1BHTR1ATDO2 | |
| SCHEMBL6726534 | 0.82 | HTR1F (0.49) | HTR1FHTR1DHTR1BHTR1A | |
| SCHEMBL6724813 | 0.81 | HTR1A (0.55) | HTR1FHTR1DHTR1BHTR1AHTR2A | |
| SCHEMBL6724521 | 0.78 | PRKAB2 (0.46) | HTR1FHTR1DHTR1B | |
| SCHEMBL6724740 | 0.77 | PRKAB2 (0.52) | HTR1FHTR1DHTR1B | |
| SCHEMBL6667683 | 0.76 | MTNR1A (0.53) | HTR1FHTR1DHTR1B | |
| SCHEMBL30267364 | 0.76 | MTNR1A (0.53) | HTR1FHTR1DHTR1B | |
| SCHEMBL6726471 | 0.76 | HTR1A (0.52) | HTR1FHTR1DHTR1BHTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6673811-B1 | TREATMENT OF ANXIETY, DEPRESSION, SLEEP DISORDER, ATTENTION DEFICIT DISORDER, ALZHEIMER'S DEMENTIA, OR SHORT-TERM MEMORY LOSS | NEUROGEN CORPORATION | 2004-01-06 | — | — | US | claimed |
| US-6673811-B1 | TREATMENT OF ANXIETY, DEPRESSION, SLEEP DISORDER, ATTENTION DEFICIT DISORDER, ALZHEIMER'S DEMENTIA, OR SHORT-TERM MEMORY LOSS | NEUROGEN CORPORATION | 2004-01-06 | — | — | US | disclosed |